Please Wait
Applying Filters...
menu
    • menu
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Mito-C

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    UroGen Reports 94.5% Six-Month Response in Phase 3 UTOPIA Trial
    UroGen Reports 94.5% Six-Month Response in Phase 3 UTOPIA Trial

    15 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/15/3295788/0/en/urogen-reports-94-5-six-month-duration-of-response-in-phase-3-utopia-trial-advancing-ugn-103-toward-potential-approval-in-recurrent-low-grade-intermediate-risk-nmibc.html

    GLOBENEWSWIRE
    15 May 2026
    Share Share
    Journal of Urology Publishes ENVISION Trial Results for ZUSDURI
    Journal of Urology Publishes ENVISION Trial Results for ZUSDURI

    30 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/30/3264559/0/en/Journal-of-Urology-Publishes-ENVISION-Trial-Results-Showing-72-2-24-Month-Duration-of-Response-with-ZUSDURI.html

    GLOBENEWSWIRE
    30 Mar 2026
    Share Share
    UroGen Pharma Issues Inducement Grants Per Nasdaq LR 5635(C)(4)
    UroGen Pharma Issues Inducement Grants Per Nasdaq LR 5635(C)(4)

    06 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/06/3251317/0/en/UroGen-Pharma-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    06 Mar 2026
    Share Share
    ZUSDURI Shows Durable CRs in Recurrent LG-IR NMIBC
    ZUSDURI Shows Durable CRs in Recurrent LG-IR NMIBC

    27 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/27/3246510/0/en/ZUSDURI-Achieves-Durable-Complete-Responses-Across-EORTC-Risk-Groups-in-Patients-with-Recurrent-LG-IR-NMIBC.html

    GLOBENEWSWIRE
    27 Feb 2026
    Share Share
    ZUSDURI Gains Permanent J-Code, Boosting Bladder Cancer Access
    ZUSDURI Gains Permanent J-Code, Boosting Bladder Cancer Access

    05 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/05/3212696/0/en/Permanent-J-Code-for-ZUSDURI-Now-in-Effect-Expanding-Patient-Access-to-Innovative-Bladder-Cancer-Therapy.html

    GLOBENEWSWIRE
    05 Jan 2026
    Share Share
    Urogen Pharma Issues Inducement Grants Per Nasdaq LR 5635(C)(4)
    Urogen Pharma Issues Inducement Grants Per Nasdaq LR 5635(C)(4)

    05 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/05/3200660/0/en/UroGen-Pharma-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    05 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.